Skip to main content
OpenTrials
Completed

NCT Number: NCT03099798

Traumatic Splenic Injury and Management (SPLENIQ Study)

OBJECTIVE:

To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury.

HYPOTHESIS:

The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS >25 and a splenic injury grade of 3 or higher.

STUDY DESIGN:

A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study.

STUDY POPULATION/DATASET:

Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging.

INTERVENTION:

All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment.

OUTCOME MEASURES:

Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging.

SAMPLE SIZE:

Approximately 100 patients will be included per year during the inclusion phase.

DATA ANALYSIS:

With regard to the prospective data linear modelling will be performed.

COLLABORATION/CONNECTION:

Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle.

TIME SCHEDULE:

Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Radboud University Medical Center, Nijmegen, Gelderland, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Splenic injury after blunt abdominal trauma (confirmed by FAST and/or CT)
  • The patient underwent NOM/SAE/splenectomy for the management of traumatic splenic injury
  • The treatment took place in the period from March 2017 to December 2018 at one of the five selected hospitals
  • 18 years or older.

Exclusion criteria

  • Insufficient knowledge of the Dutch language
  • Patients who died during or after treatment are (of course) excluded for questionnaires and MRI, not for clinical outcomes

Exclusion for MRI only:

  • Patients treated with SAE: patients who do not want to or are not able to undergo an MRI abdomen (for example pregnant women or other contraindications for MRI). Patients excluded for MRI still need to fill out the questionnaires. Also, their clinical outcomes will be processed in the database.

Treatment and study plan

questionnaires

Other

All patients will complete a number of questionnaires at different time points.

  • SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ
  • 1 week, 1 month, 3, 6 and 12 months after treatment

MRI abdomen

Diagnostic Test

Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.

Primary outcomes

  1. Quality of Life: baseline (within 1 week after treatment)

    Time frame: One week after treatment

    WHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires

  2. Quality of life: 1 month follow-up

    Time frame: One month after treatment

    WHOQoL-Bref questionnaire

  3. Quality of life: 3 months follow-up

    Time frame: Three months after treatment

    WHOQoL-Bref questionnaire

  4. Quality of life: 6 months follow-up

    Time frame: Six months after treatment

    WHOQoL-Bref questionnaire

  5. Quality of life: one year follow-up

    Time frame: One year after treatment

    WHOQoL-Bref questionnaire

  6. Change in health status: SF-12

    Time frame: One week, 1 month and 3, 6 and 12 months after treatment

    SF-12 questionnaire

  7. Change in health related quality of life: EQ-5D-5L

    Time frame: One week, 1 month and 3, 6 and 12 months after treatment

    EQ-5D-5L questionnaire

Secondary outcomes

  1. Clinical Outcome

    Time frame: One year follow-up

    Data obtained from the patient records (e.g. complications, need for re-intervention, hospital stay, return to daily activities)

  2. Cost-effectiveness

    Time frame: One year follow-up

    The overall cost-effectiveness will be assessed with the iPCQ and iMCQ questionnaires, completed at different time points

  3. Imaging Outcome after Embolization (one month after treatment)

    Time frame: One month after embolization

    Splenic morphological characteristics (e.g. volume, necrosis, splenosis, calcifications or chronic infarction morphology)

  4. Imaging Outcome after Embolization (one year after treatment)

    Time frame: One year after embolization

    Splenic morphological characteristics (e.g.volume, necrosis, splenosis, calcifications or chronic infarction morphology)

  5. Splenic Artery Embolization characteristics

    Time frame: One year follow-up

    Difference between proximal versus distal embolization

  6. Prognostic factors for failure of Non-Operative Management

    Time frame: One year follow-up

    A recent study suggests that there are prognostic factors for failure of NOM in the treatment of adults with (blunt) splenic injury. Strong evidence exists for: age of 40 years or above, Injury Severity Score (ISS) of 25 or greater and American Association for the Surgery of Trauma (AAST) splenic injury grade of 3 or greater.

Sponsors and collaborators

Lead sponsor

Elisabeth-TweeSteden Ziekenhuis

Other

Collaborators

  • Albert Schweitzer Hospital
  • Amphia Hospital
  • Amsterdam UMC, location VUmc
  • Erasmus Medical Center
  • Isala
  • Leiden University Medical Center
  • Maasstad Hospital
  • Medisch Spectrum Twente
  • Radboud University Medical Center
  • Tilburg University

Registry information

Official study title

Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma

Acronym: SPLENIQ

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Apr 4, 2017
Registry last updated
Apr 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.